3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Stomach Neoplasms
6
Gastritis
5
Lymphoma, B-Cell, Marginal Zone
4
Dyspepsia
4
Peptic Ulcer
3
Lymphoma
3
Neoplasms
2
Stomach Ulcer
1
Skin Neoplasms
1
Pseudomyxoma Peritonei
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Helicobacter Infections
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Fever
1
Familial primary gastric lymphoma
1
Cystectomy
1
Chemotherapy Effect
1
Brain Neoplasms
1
Astrocytoma
1
Appendiceal Neoplasms
1
Agammaglobulinemia
1
Interventions
Lenalidomide
2
ofatumumab
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
SARS-CoV-2 inactivated vaccines
1
Influenza Vaccines
1
Immunoglobulins
1
Hizentra
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Agammaglobulinemia
×
Amoxicillin
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled